Combined angiotensin receptor antagonism and neprilysin inhibition

Circulation

Volumn 133, Issue 11, 2016, Pages 1115-1124

  Hubers, Scott A ^a   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heart failure; Natriuretic peptides; Pharmacology; Prescription drugs

Indexed keywords

ANGIOTENSIN RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL PLUS VALSARTAN; 3 (1 BIPHENYL 4 YLMETHYL 3 CARBOXY 1 BUTYLCARBAMOYL)PROPIONIC ACID; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; BRADYKININ; DRUG COMBINATION; ENALAPRIL; ENZYME INHIBITOR; NATRIURETIC FACTOR; OMAPATRILAT; PRODRUG; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZEPINE DERIVATIVE; VALSARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; COUGHING; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; ABNORMALITIES, DRUG-INDUCED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CONTRAINDICATIONS; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; ECONOMICS; FEMALE; FOLLOW UP; HEART STROKE VOLUME; KIDNEY; METABOLISM; MULTICENTER STUDY (TOPIC); PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ABNORMALITIES, DRUG-INDUCED; AMINOBUTYRATES; ANGIOEDEMA; ANGIOTENSIN RECEPTOR ANTAGONISTS; BIPHENYL COMPOUNDS; BRADYKININ; DRUG COMBINATIONS; DRUG COSTS; DRUG SYNERGISM; ENALAPRIL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYPERKALEMIA; HYPERTENSION; KIDNEY; MULTICENTER STUDIES AS TOPIC; NATRIURETIC PEPTIDES; NEPRILYSIN; PREGNANCY; PRODRUGS; PROSPECTIVE STUDIES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TETRAZOLES; THIAZEPINES; VALSARTAN;

EID: 84961805886     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.018622     Document Type: Article

References (58)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfghi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322. doi: 10.1161/CIR.0000000000000152.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-e327. doi: 10.1161/CIR.0b013e31829e8776.
3. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50:401-414. doi: 10.1177/0091270009343932.
4. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
5. Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176:630-639. doi: 10.1016/j.ijcard.2014.08.032.
6. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387-1395. doi: 10.1016/S0140-6736(12)61227-6.
7. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natri-uretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(pt 1):83-88.
8. Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, Nagai R, Komuro I. Atrial natri-uretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun. 2004;322:310-319. doi: 10.1016/j.bbrc.2004.07.119.
9. Fujita S, Shimojo N, Terasaki F, Otsuka K, Hosotani N, Kohda Y, Tanaka T, Nishioka T, Yoshida T, Hiroe M, Kitaura Y, Ishizaka N, Imanaka-Yoshida K. Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating infammation via endothe-lin-1/endothelin receptor A cascade. Heart Vessels. 2013;28:646-657. doi: 10.1007/s00380-012-0311-0.
10. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fbroblasts. J Clin Invest. 1998;101:812-818. doi: 10.1172/JCI119883.
11. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen YF. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofbroblast transformation in mouse cardiac fbroblasts. Circ Res. 2008;102:185-192. doi: 10.1161/CIRCRESAHA.107.157677.
12. Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fbroblasts: fbrosis, myofbroblast conversion, proliferation, and infammation. Circ Res. 2004;94:453-461. doi: 10.1161/01.RES.0000117070.86556.9F.
13. Izumiya Y, Araki S, Usuku H, Rokutanda T, Hanatani S, Ogawa H. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myo-cardial superoxide production and cardiac remodeling. Int J Vasc Med. 2012;2012:246058. doi: 10.1155/2012/246058.
14. Moro C, Lafontan M. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol. 2013;304:H358-H368. doi: 10.1152/ajpheart.00704.2012.
15. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-1351.
16. Schmitt M, Gunaruwan P, Payne N, Taylor J, Lee L, Broadley AJ, Nightingale AK, Cockcroft JR, Struthers AD, Tyberg JV, Frenneaux MP. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol. 2004;24:911-917. doi: 10.1161/01.ATV.zhq0504.7914.
17. Forfa PR, Lee M, Tunin RS, Mahmud M, Champion HC, Kass DA. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007;49:1079-1088. doi: 10.1016/j.jacc.2006.08.066.
18. Chen HH. Heart failure: a state of brain natriuretic peptide defciency or resistance or both! J Am Coll Cardiol. 2007;49:1089-1091. doi: 10.1016/j. jacc.2006.12.013.
19. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355-360. doi: 10.1161/CIRCHEARTFAILURE.110.960260.
20. Lee CY, Chen HH, Lisy O, Swan S, Cannon C, Lieu HD, Burnett JC Jr. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a frst-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49:668-673. doi: 10.1177/0091270009336233.
21. McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14:62-69. doi: 10.1007/s11906-011-0244-5.
22. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43. doi: 10.1056/NEJMoa1100171.
23. McDowell G, Nicholls DP. The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs. 1999;8:79-84. doi: 10.1517/13543784.8.1.79.
24. Cleland JG, Swedberg K. Lack of effcacy of neutral endopeptidase inhibitor ecadotril in heart failure: the International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet. 1998;351:1657-1658.
25. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men; effects on hemo-dynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26(pt 2):1160-1166.
26. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endo-peptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998;97:2323-2330.
27. Stephenson SL, Kenny AJ. Metabolism of neuropeptides: hydrolysis of the angiotensins, bradykinin, substance P and oxytocin by pig kidney microvillar membranes. Biochem J. 1987;241:237-247.
28. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71:1501-1507.
29. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407-416.
30. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
31. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bra-dykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292. doi: 10.1056/NEJM199810293391804.
32. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plas-minogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
33. Bas M, Hoffmann TK, Kojda G. Icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015;372:1867-1868. doi: 10.1056/NEJMc1503671.
34. Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, Clarke A, Biggerstaff F, Hillier C, McMurray JJ. Effects of neutral endopep-tidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2014;32:13-18. doi: 10.1111/1755-5922.12053.
35. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998;275(pt 2):F410-F414.
36. Rademaker MT, Charles CJ, Cooper GJ, Coy DH, Espiner EA, Lewis LK, Nicholls MG, Richards AM. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension. 2002;39:93-98.
37. Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995;38:1689-1700.
38. Feng L, Karpinski PH, Sutton P, Liu Y, Hook DF, Hu B, Blacklock TJ, Fanwick PE, Prashad M, Godtfredsen S, Ziltener C. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53:275-276.
39. Entresto Prescribing Information. Drugs@FDA Web site. http://www. accessdata.fda.gov/drugsatfda-docs/label/2015/207620Orig1s000lbl.pdf. Updated July 7, 2015. Accessed August 21, 2015.
40. Gan L, Langenickel T, Petruck J, Kode K, Rajman I, Chandra P, Zhou W, Rebello S, Sunkara G. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56:78-86. doi: 10.1002/jcph.571.
41. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. Identifcation of a novel gene family encoding human liver-specifc organic anion transporter LST-1. J Biol Chem. 1999;274:17159-17163.
42. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000;275:23161-23168. doi: 10.1074/jbc.M001448200.
43. Smith NF, Figg WD, Sparreboom A. Role of the liver-specifc transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol. 2005;1:429-445. doi: 10.1517/17425255.1.3.429.
44. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacoki-netics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther. 2006;79:427-439. doi: 10.1016/j.clpt.2006.01.011.
45. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004. doi: 10.1056/NEJMoa1409077.
46. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15:1062-1073. doi: 10.1093/eurjhf/hft052.
47. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2014;16:817-825. doi: 10.1002/ejhf.115.
48. Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997-1003. doi: 10.1016/j. jacc.2008.04.069.
49. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255-1266. doi: 10.1016/S0140-6736(09)61966-8.
50. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Effcacy and safety of LCZ696, a frst-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698-705. doi: 10.1161/HYPERTENSIONAHA.113.02002.
51. Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2013;23:470-478. doi: 10.1097/FPC.0b013e328363c137.
52. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol. 1997;136:153-158.
53. Brown NJ, Ray WA, Snowden M, Griffn MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13. doi: 10.1016/S0009-9236(96)90161-7.
54. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, Levy E. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642. doi: 10.1001/archinte.165.14.1637.
55. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.
56. Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, Robertson JI. Factors related to frst dose hypotensive effect of captopril: prediction and treatment. BMJ. (Clin Res Ed). 1983;286:832-834.
57. Voors AA, Gori M, Liu LC, Claggett B, Zile MR, Pieske B, McMurray JJ, Packer M, Shi V, Lefkowitz MP, Solomon SD; PARAMOUNT Investigators. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510-517. doi: 10.1002/ejhf.232.
58. Ollendorf DA, Sandhu AT, Chapman R, Heidenreich PA, Russo E, Shore KK, Synnott P, Travers K, Weissberg J, Pearson SD. CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. California Technology Assessment Forum website. http://ctaf.org/sites/default/fles/u148/CHF-Draft- Report-091115.pdf. September 11, 2015. Accessed November 14, 2015.